NURL — Neural Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- CA$1.33m
- CA$1.17m
Annual balance sheet for Neural Therapeutics, fiscal year end - July 31st, CAD millions except per share, conversion factor applied.
2022 July 31st | 2023 July 31st | 2024 July 31st | 2025 July 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Cash and Short Term Investments | 0.372 | 0.273 | 0.067 | 0.165 |
| Net Total Receivables | 0.051 | 0.069 | 0.028 | 0.007 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 0.455 | 0.351 | 0.096 | 0.192 |
| Total Assets | 0.455 | 0.351 | 0.096 | 0.192 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Current Liabilities | 0.464 | 0.473 | 0.306 | 0.175 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 0.464 | 0.613 | 0.78 | 0.92 |
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Total Equity | -0.009 | -0.262 | -0.684 | -0.728 |
| Total Liabilities & Shareholders' Equity | 0.455 | 0.351 | 0.096 | 0.192 |
| Total Common Shares Outstanding |